[{"id":"056fe673-cdf1-43ac-850b-4889f543f569","acronym":"","url":"https://clinicaltrials.gov/study/NCT03169790","created_at":"2021-01-18T15:37:43.674Z","updated_at":"2025-02-25T12:26:42.620Z","phase":"Phase 1/2","brief_title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","source_id_and_acronym":"NCT03169790","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 12/23/2021","study_completion_date":" 12/23/2021","last_update_posted":"2025-02-24"},{"id":"ba15135a-7176-4f0e-a8cc-e6c040cf6509","acronym":"","url":"https://clinicaltrials.gov/study/NCT04574583","created_at":"2021-01-18T21:50:28.241Z","updated_at":"2025-02-25T17:00:40.932Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)","source_id_and_acronym":"NCT04574583","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 02/07/2023","primary_completion_date":" 02/07/2023","study_txt":" Completion: 05/19/2023","study_completion_date":" 05/19/2023","last_update_posted":"2025-02-03"},{"id":"42863ddc-f4db-4ccc-bee0-c2c0b6477bd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03300817","created_at":"2024-01-03T14:17:29.800Z","updated_at":"2024-07-02T16:34:26.572Z","phase":"Phase 1","brief_title":"MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer","source_id_and_acronym":"NCT03300817","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6 • MUC1 • CRP","pipe":"","alterations":" ","tags":["IL6 • MUC1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/23/2021","primary_completion_date":" 09/23/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-13"},{"id":"4c345493-ab62-410a-b773-a42c655f0249","acronym":"PDC-LUNG-101","url":"https://clinicaltrials.gov/study/NCT03970746","created_at":"2021-01-18T19:31:48.798Z","updated_at":"2024-07-02T16:35:31.964Z","phase":"Phase 1/2","brief_title":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","source_id_and_acronym":"NCT03970746 - PDC-LUNG-101","lead_sponsor":"PDC*line Pharma SAS","biomarkers":" CD8 • HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["CD8 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed • PDC*lung"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 09/10/2019","start_date":" 09/10/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-24"},{"id":"2b2a33f0-7d89-49c3-9ce4-c97417b76c39","acronym":"","url":"https://clinicaltrials.gov/study/NCT03353675","created_at":"2021-01-18T16:33:23.634Z","updated_at":"2025-02-25T14:37:45.397Z","phase":"Phase 2","brief_title":"A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03353675","lead_sponsor":"Transgene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • mesmulogene ancovacivec (TG4010)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 11/20/2019","primary_completion_date":" 11/20/2019","study_txt":" Completion: 02/17/2021","study_completion_date":" 02/17/2021","last_update_posted":"2022-01-11"},{"id":"638f674b-6661-4749-93fa-511ca0e2c24f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02823990","created_at":"2021-01-18T13:50:49.883Z","updated_at":"2025-02-25T14:36:27.825Z","phase":"Phase 2","brief_title":"TG4010 and Nivolumab in Patients With Lung Cancer","source_id_and_acronym":"NCT02823990","lead_sponsor":"Karen Kelly","biomarkers":" ALK","pipe":" | ","alterations":" ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • mesmulogene ancovacivec (TG4010)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 02/24/2021","primary_completion_date":" 02/24/2021","study_txt":" Completion: 02/24/2021","study_completion_date":" 02/24/2021","last_update_posted":"2021-10-13"},{"id":"95ff12bc-e7be-49e9-8642-0f09820d5e2a","acronym":"BK2016.01","url":"https://clinicaltrials.gov/study/NCT03146637","created_at":"2021-01-19T14:08:20.070Z","updated_at":"2024-07-02T16:36:35.301Z","phase":"Phase 2","brief_title":"Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer","source_id_and_acronym":"NCT03146637 - BK2016.01","lead_sponsor":"Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e activated CIK and bispecific antibody • activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 01/27/2021","primary_completion_date":" 01/27/2021","study_txt":" Completion: 01/28/2021","study_completion_date":" 01/28/2021","last_update_posted":"2021-02-01"},{"id":"ce6cc088-a55e-4a98-8743-91177e066c1d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01899599","created_at":"2021-01-18T08:32:51.601Z","updated_at":"2024-07-02T16:36:39.724Z","phase":"Phase 2","brief_title":"PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer","source_id_and_acronym":"NCT01899599","lead_sponsor":"Glycotope GmbH","biomarkers":" MUC16","pipe":" | ","alterations":" TA-MUC1 positive","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TA-MUC1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PankoMab-GEX (gatipotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 216","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 04/20/2017","primary_completion_date":" 04/20/2017","study_txt":" Completion: 07/28/2017","study_completion_date":" 07/28/2017","last_update_posted":"2020-10-22"},{"id":"c51c4542-8655-4942-b449-a1d17ae733cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03384316","created_at":"2021-01-18T16:42:00.383Z","updated_at":"2024-07-02T16:36:41.287Z","phase":"Phase 1","brief_title":"Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer","source_id_and_acronym":"NCT03384316","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ETBX-011 • ETBX-051 • ETBX-061"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 05/22/2018","primary_completion_date":" 05/22/2018","study_txt":" Completion: 08/24/2020","study_completion_date":" 08/24/2020","last_update_posted":"2020-09-09"},{"id":"9d759b1e-1179-43f0-84f0-2e00510ccf08","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840994","created_at":"2021-01-18T13:56:43.083Z","updated_at":"2024-07-02T16:36:49.478Z","phase":"Phase 1","brief_title":"A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02840994","lead_sponsor":"Bavarian Nordic","biomarkers":" ALK • ROS1 • CEACAM5","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression","tags":["ALK • ROS1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2020-02-27"},{"id":"d1de477e-4158-46d8-b4ef-18de32556c68","acronym":"","url":"https://clinicaltrials.gov/study/NCT00088413","created_at":"2021-01-18T00:15:43.686Z","updated_at":"2024-07-02T16:37:00.590Z","phase":"Phase 1/2","brief_title":"PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer","source_id_and_acronym":"NCT00088413","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CEACAM5","pipe":" | ","alterations":" MUC1 expression • HLA-A2 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC1 expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim) • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 07/21/2004","start_date":" 07/21/2004","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 05/31/2018","study_completion_date":" 05/31/2018","last_update_posted":"2019-04-16"},{"id":"0461c7a7-21e2-4e81-904b-eaaa59fe9275","acronym":"","url":"https://clinicaltrials.gov/study/NCT00773097","created_at":"2021-01-18T02:55:17.301Z","updated_at":"2024-07-02T16:37:04.205Z","phase":"Phase 2","brief_title":"Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma","source_id_and_acronym":"NCT00773097","lead_sponsor":"Robert Schoen","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 10/01/2011","primary_completion_date":" 10/01/2011","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2019-01-07"},{"id":"bd47dd42-9e42-4495-884c-94076f8c36c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02270372","created_at":"2021-01-18T10:40:37.901Z","updated_at":"2024-07-02T16:37:10.668Z","phase":"Phase 1b","brief_title":"Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer","source_id_and_acronym":"NCT02270372","lead_sponsor":"Cascadian Therapeutics Inc.","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e varlilumab (CDX 1127) • ONT-10"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2018-05-17"},{"id":"f7a6174e-7fc7-43b8-86df-9aff3711091d","acronym":"EMR 63325-015","url":"https://clinicaltrials.gov/study/NCT01496131","created_at":"2021-01-18T06:16:08.326Z","updated_at":"2024-07-02T16:37:13.158Z","phase":"Phase 2","brief_title":"Tecemotide (L-BLP25) in Prostate Cancer","source_id_and_acronym":"NCT01496131 - EMR 63325-015","lead_sponsor":"EMD Serono","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • goserelin acetate • Stimuvax (tecemotide) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 10/24/2011","start_date":" 10/24/2011","primary_txt":" Primary completion: 11/25/2016","primary_completion_date":" 11/25/2016","study_txt":" Completion: 11/25/2016","study_completion_date":" 11/25/2016","last_update_posted":"2018-03-09"},{"id":"7c6bfff4-5011-444a-90d9-1ef097eadebd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01462513","created_at":"2021-01-18T06:05:01.468Z","updated_at":"2024-07-02T16:37:13.981Z","phase":"Phase 2","brief_title":"L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases","source_id_and_acronym":"NCT01462513","lead_sponsor":"Prof. Dr. Carl Schimanski","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stimuvax (tecemotide)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 12/31/2017","primary_completion_date":" 12/31/2017","study_txt":" Completion: 01/31/2018","study_completion_date":" 01/31/2018","last_update_posted":"2018-02-13"},{"id":"f3810cf4-5645-4a8e-aaa3-0c8ad990325f","acronym":"FINGERPRINT","url":"https://clinicaltrials.gov/study/NCT01731587","created_at":"2021-01-18T07:34:17.378Z","updated_at":"2025-02-25T14:49:39.621Z","phase":"Phase 1","brief_title":"Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01731587 - FINGERPRINT","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" TGFB1 • IFNA1 • CRP","pipe":"","alterations":" ","tags":["TGFB1 • IFNA1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Stimuvax (tecemotide) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2001","start_date":" 01/01/2001","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2017-02-28"},{"id":"50680306-c8c0-4e02-9bf0-71ac36cdd8cd","acronym":"SPRINT","url":"https://clinicaltrials.gov/study/NCT01507103","created_at":"2021-01-18T06:19:59.567Z","updated_at":"2025-02-25T14:49:33.046Z","phase":"Phase 2","brief_title":"Tecemotide (L-BLP25) in Rectal Cancer","source_id_and_acronym":"NCT01507103 - SPRINT","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" MSI • CD8 • IFNG • MLH1 • MSH6 • MUC1 • MSH2 • CEACAM5 • ISG20","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • CD8 • IFNG • MLH1 • MSH6 • MUC1 • MSH2 • CEACAM5 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • Stimuvax (tecemotide) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2017-01-13"}]